HELP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Based on the investor's beginner level, long-term investment strategy, and available capital of $50,000-$100,000, Helus Pharma (HELP) is a good buy. The stock has promising catalysts, including strong clinical trial results, FDA breakthrough therapy designation, and a growing market for mental health therapeutics. Despite the lack of immediate trading signals and weak financials, the long-term growth potential outweighs the risks.
The MACD is positively expanding, indicating bullish momentum. RSI is in the neutral zone at 75.834, and moving averages are converging, suggesting no strong directional bias. The stock is trading near its resistance level (R1: 7.619), which could act as a short-term barrier.
FDA Breakthrough Therapy designation for HLP003 with promising Phase 3 trials.
Positive Phase 2 trial results for SPL026 in treatment-resistant depression.
Appointment of a former Pfizer Chief Medical Officer to the board.
Significant market potential for mental health therapeutics, projected to exceed $40 billion.
Strong analyst rating with a $22 price target and potential for 100%-200% share rally.
Weak financials with no revenue and a net income of -$42.67 million in Q3
Lack of significant hedge fund or insider trading activity.
No recent congress trading data or valuation metrics available.
In Q3 2026, the company reported no revenue growth, a net income of -$42.67 million (up 465.96% YoY), and an EPS of -1 (up 163.16% YoY). Gross margin remained at 0%. While losses are narrowing, the financials remain weak overall.
Jefferies initiated coverage with a Buy rating and a $22 price target, citing strong clinical catalysts and a high probability of success for HLP003 in Phase 3 trials. The analyst expects significant upside potential in 2026.
